AMENDMENT

Please amend the claims as set out below. This listing of claims will replace all previous versions.

- 1. (Currently amended) A tripeptide or tetrapeptide or an alkyl ester thereof comprising a proteolytic enzyme cleavable amino acid moiety that is connect to as a drug or pharmacologically active site or pharmacologically active group transport and delivery system with the proviso that it is not prolyl-m-sarcolysyl-p-fluoro-phenylalanine.
- 2. (Currently amended) The tripeptide or tetrapeptide of claim 1, which is an alkyl ester with the alkyl group being a methyl or an ethyl group, preferably an ethyl group.
- 3. (Currently amended) The tripeptide or tetrapeptide of claim 1, wherein the proteolytic enzyme cleavable amino acid moiety is a not terminal moiety.
- 4. (Currently amended) The tripeptide or tetrapeptide of claim 1 comprising a not terminal optionally substituted phenylalanyl moiety.
- 5. (Currently amended) The tripeptide of claim 1 anyone of the preceding claims that is selected from the group consisting of substituted or unsubstituted Phe-Phe-Pro, Pro-Phe-Phe, Phe-Phe-Ser, Ser-Phe-Phe, Phe-Phe-Asn, Asn-Phe-Phe, Phe-Gly-Phe-Val (Seq. Id. No. 1), Val-Phe-Gly-Phe (Seq. Id. No. 2), Phe-Arg-Phe-His (Seq. Id. No. 3), His-Phe-Arg-Phe (Seq. Id. No. 4), Phe-Arg-Val, Val-Arg-Phe, and Pro-Phe-Phe.
- 6. (Currently amended) The tripeptide or tetrapeptide of claim 1, wherein the terminal Phe is fluoro substituted in para position[[,]]-in particular the peptide Pro-Phe p-F-Phe.
- 7. (Currently amended) The tripeptide or tetrapeptide of claim 1 wherein the proteolytic enzyme cleavable amino acid moiety is substituted with a substituent sufficiently reactive to be useful in drug coupling reactions, with the proviso that said substituent is not -- N(CH₂—CH₂--Cl)₂ in meta position on the not terminal Phe of Pro-Phe-p-F-Phe.

8. (Currently amended)	The tripeptide or tetrapeptide of claim 7 wherein the
proteolytic enzyme cleavable amino acid i	moiety is or comprises Phe.
O (Canaalad)	

- 9. (Canceled)
- 10. (Canceled)
- 11. (Currently amended) The tripeptide or tetrapeptide of claim $\frac{10}{1}$ wherein the drug is adriamycin.
 - 12. (Canceled)
 - 13. (Canceled)
 - 14. (Canceled)
 - 15. (Canceled)
- 16. (Currently amended) A pharmaceutical composition comprising a tripeptide or a tetrapeptide of claim $10 \ \underline{1}$.
 - 17. (Canceled)
- 18. (Currently amended) The tripeptide or tetrapeptide of claim 1 that is a substituted or unsubstituted Pro-Phe-Phe.
 - 19. (Canceled)
 - 20. (New) The tripeptide of claim 6 wherein the peptide is Pro-Phe-p-F-Phe.